An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.
Experimental Treatment Acquiring Popularity Via Social Media
The experimental drug, which is still in clinical trials, is being advertised by online personalities for its alleged weight-reducing properties. Viewers are encouraged to contact these accounts privately for supplier links, while also receiving discount codes.
Active Trade on Social Networks
Additionally, a flourishing market exists on Telegram, where communities with numerous of participants share comparison images, injection guides and assertions of next-day UK delivery. Sellers market the drug there before directing customers to WhatsApp for transactions.
Learning About Retatrutide
Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies indicate it could help patients reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Medical Experts Voice Concerns
However, doctors and pharmacists have cautions that the distribution of what is still an unapproved drug in the UK is a cause for concern and could result in individuals administering products of unknown origin.
Several experts stated the demand for the experimental drug could be connected to the increasing price of licensed weight loss products such as Mounjaro.
Legal Position and Enforcement
Marketing the unapproved drug on TikTok or Telegram is prohibited in the UK, as it is an unlicensed medication that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.
Some influencers try to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and supply can still breach pharmaceutical, advertising, and consumer regulations, potentially leading to fines, prosecution or prison.
Platform Response and Content Removal
Based on the social media company, the service has removed violative material and prohibited related keywords and query recommendations. The organization said it was committed to keeping the platform safe and investing in strengthening enforcement strategies.
Online Marketplace Activities
Research also discovered communities with up to 9,000 members marketing retatrutide using Telegram's built-in discovery tool, which operates like a online catalog. Typing “retatrutide” instantly brings up groups with thousands of users, populated with images of weight loss, glowing reviews and detailed guides for preparing or administering at home.
After minutes of entering one community, a vendor posted WhatsApp details, where the majority of transactions take place. The seller provided an guidebook and promised delivery within two days. When questioned whether the substance was authentic, one seller responded: “You can’t be sure.” Another shared a image of a supposed testing documentation. None asked about weight, medical conditions or past usage.
Product Information and Costs
Inside these groups, posts show dark colored packages with postal service labels, stating to contain new batches. One message stated: “It took eight of us to load them this morning.”
Buyers can select between dry substance containers, mixed at home with sterile water, or pre-filled injectors typically priced at 160 pounds for 20mg. When questioned how much time a injector should last, sellers give conflicting answers varying between a several days to “depends on your body”.
Service Oversight and Safety Measures
A spokesperson for Telegram said it regularly monitored dangerous material on its service including content that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are administering substances they can’t verify. Although the science behind retatrutide is sound, these digital products may not include what they claim,” said Jason Murphy, the head of pharmacy at a pharmacy service.
Dr Crystal Wyllie of an online medical service connected the increase in interest to current price rises for authorized weight-loss medications such as Mounjaro. “With costs rising, patients are using online platforms. But counterfeit injections are extremely dangerous. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she explained.
Her team has already encountered patients injured by self-injection from unverified suppliers. “We understand the disappointment, but purchasing from Telegram or WhatsApp is gambling with your health,” said Wyllie. “These materials could be contaminated or incorrectly dosed.”
Producer Position
A representative from Eli Lilly stated the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this point no one can sell [it] for human use,” they said, noting that any item “falsely representing itself as a company investigational product not yet authorized … may expose patients to possibly serious medical dangers”.
